These findings highlight the potential of self-complementary AAVs to reduce dose requirements, minimize toxicity, and broaden ...

The "Adeno-Associated Virus (AAV) Vectors in Gene Therapy – Market Insight, Epidemiology and Market Forecast – 2030" drug pipelines has been added to ResearchAndMarkets.com’s offering. This report ...

PHILADELPHIA--(BUSINESS WIRE)--VintaBio, a biotech manufacturing technology company specializing in high-yield, high-purity viral vector production for reliable gene therapy access, will present ...

Oxford, UK – 11 March 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or the “Company"), a leading gene and cell therapy group, is pleased to announce that it has completed its deal with ...

The "Adeno-Associated Viral (AAV) Vector Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Therapy, Therapeutic Area, Route of Administration, Scale of Operation and ...

Efficient viral vector production is essential for the cost-effective manufacture of cell and gene therapies. Many of the current production workflows are reliant on basal media in batch-mode, which ...

The hyper-intensified process delivers significant increases in AAV yield and full capsid percentage through a novel adherent, perfusion-based manufacturing approach VintaBio, a biotech manufacturer ...

HOUSTON, May 12, 2025 /PRNewswire/ -- PackGene Biotech, Inc. announced today six presentations at the American Society of Gene & Cell Therapy (ASGCT) 28 th annual meeting in New Orleans, May 13-17, ...

There are a number of considerations that can help streamline the pathway to the clinic. One of the first is which vector ...

According to Nova One Advisor, the global viral vector & plasmid DNA manufacturing size is calculated at USD 7.54 billion in 2025 and is expected to surpass around USD 27.71 billion by 2034, growing ...